Liver Fibrosis Market Report and Forecast 2024-2032

Liver Fibrosis Market Report and Forecast 2024-2032


Liver Fibrosis Market Report and Forecast 2024-2032

Liver Fibrosis Market Outlook

The liver fibrosis market size was valued at USD 2.32 billion in 2023, driven by the increasing trend towards non-invasive diagnostic methods across the major markets. The market size is anticipated to grow at a CAGR of 7.7% during the forecast period of 2024-2032 to achieve a value of USD 4.52 billion by 2032.

Liver Fibrosis: Introduction

Liver fibrosis is the excessive accumulation of extracellular matrix proteins, including collagen, that occurs in most types of chronic liver diseases. It's the liver's response to injury or inflammation, where normal liver tissue gradually gets replaced by scar tissue. This scarring process can eventually disrupt liver function, leading to cirrhosis if untreated. Factors like chronic hepatitis, alcohol abuse, and fatty liver disease contribute to fibrosis. Early stages are often reversible with treatment and lifestyle changes.

Key Trends in the Liver Fibrosis Market

There's a growing trend towards non-invasive diagnostic methods, such as elastography and biomarker tests, to assess liver fibrosis. These methods are favored for their ability to reduce patient discomfort and the risks associated with liver biopsies, while allowing for more frequent monitoring of liver health.

Personalized medicine is becoming more prominent, with treatments being tailored based on the individual's genetic makeup, stage of fibrosis, and underlying cause. This approach aims to improve treatment efficacy and patient outcomes.

Research and development of antifibrotic drugs are intensifying, with several compounds in various stages of clinical trials. These therapies aim to halt the progression of fibrosis, promote fibrosis regression, and improve liver function.

There's an increasing focus on combination therapies that target multiple pathways involved in the progression of liver fibrosis. This approach aims to enhance treatment effectiveness compared to monotherapy options.

Public health initiatives promoting liver health, and awareness about conditions leading to liver fibrosis, like hepatitis, alcohol abuse, and fatty liver disease, are on the rise. Preventive measures, including vaccination, lifestyle modifications, and regular screenings, are emphasized to reduce the incidence of liver fibrosis.

Digital health solutions, including mobile apps and telemedicine, are being increasingly used for patient monitoring and management. These technologies support remote patient monitoring, medication adherence, and patient education, contributing to better disease management and patient outcomes.

Liver Fibrosis Market Segmentation

Market Breakup by Condition
  • Chronic Liver Diseases
  • Hepatitis C
  • Nonalcoholic Steatohepatitis
Market Breakup by Treatment
  • Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
  • ACE Inhibitors
  • Hepatotropic Drug
  • Others
Market Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Stores and Pharmacy
  • Online Providers
Market Breakup by End User
  • Hospitals
  • Clinics
  • Others
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
Liver Fibrosis Market Overview

In North America, the liver fibrosis market is advanced, characterized by significant research in liver diseases and a strong emphasis on early diagnosis and treatment. The region has a high prevalence of liver-related conditions due to factors like obesity and hepatitis C. This drives demand for non-invasive diagnostic tests and innovative treatment options. The U.S. leads in drug development and the adoption of novel therapies, supported by a well-established healthcare infrastructure and proactive patient advocacy groups.

Europe's market is marked by comprehensive healthcare systems and a focus on healthcare innovation. The region benefits from concerted efforts in research, particularly in understanding liver diseases and developing antifibrotic therapies. Public health initiatives aimed at reducing alcohol consumption and managing metabolic syndrome factors contribute to the market dynamics. The EU's regulatory framework supports the development and fast-track approval of advanced therapies, ensuring access to cutting-edge treatment for liver fibrosis.

Japan's market for liver fibrosis is influenced by a high standard of healthcare and a strong focus on research and technological innovation. The country has a notable prevalence of liver diseases, particularly hepatitis B and C, driving the demand for effective treatment options. Japan's rapid adoption of non-invasive diagnostic techniques and advanced therapies, coupled with substantial government investment in healthcare, makes it a leading market in the Asia-Pacific region for liver fibrosis treatment and management.

Liver Fibrosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
  • F. Hoffmann-La Roche
  • Mylan N.V.
  • Sanofi
  • GlaxoSmithKline plc
  • AstraZeneca
  • Johnson & Johnson
  • Merck & Co.
  • Bristol-Myers Squibb
  • Vertex Pharmaceuticals
  • FibroGen, Inc.
  • Pharmaxis
  • Dicerna Pharmaceuticals, Inc.
  • Dynavax Technologies
  • GlaxoSmithKline plc
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Liver Fibrosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Success Rate
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Liver Fibrosis Epidemiology Analysis – 7MM
6.1 7MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3 EU-4 and United Kingdom Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.1 Germany Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.2 France Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.3 Italy Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.4 Spain Liver Fibrosis Epidemiology Forecast (2017-2032)
6.3.5 United Kingdom Liver Fibrosis Epidemiology Forecast (2017-2032)
6.4 Japan Liver Fibrosis Epidemiology Forecast (2017-2032)
7 Liver Fibrosis Market Overview – 7MM
7.1 Liver Fibrosis Market Historical Value (2017-2023)
7.2 Liver Fibrosis Market Forecast Value (2024-2032))
8 Liver Fibrosis Market Landscape-7MM
8.1 Liver Fibrosis Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Liver Fibrosis Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Liver Fibrosis Treatment Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Liver Fibrosis Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.3 Porter’s Five Forces Model
11.4 Key Demand Indicators
11.5 Key Price Indicators
11.6 Industry Events, Initiatives, and Trends
11.7 Value Chain Analysis
12 Liver Fibrosis Market Segmentation -7MM
12.1 Liver Fibrosis Market by Condition
12.1.1 Market Overview
12.1.2 Chronic Liver Diseases
12.1.3 Hepatitis C
12.1.4 Nonalcoholic Steatohepatitis
12.2 Liver Fibrosis Market by Treatment
12.2.1 Market Overview
12.2.2 Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
12.2.3 ACE Inhibitors
12.2.4 Hepatotropic Drug
12.2.5 Others
12.3 Liver Fibrosis Market by Distribution Channel
12.3.1 Market Overview
12.3.2 Hospital pharmacies
12.3.3 Retail Stores and Pharmacy
12.3.4 Online Providers
12.4 Liver Fibrosis Market by End User
12.4.1 Market Overview
12.4.2 Hospitals
12.4.3 Clinics
12.4.4 Others
12.5 Liver Fibrosis Market by Region
12.5.1 Market Overview
12.5.2 United States
12.5.3 EU-4 and the United Kingdom
12.5.3.1 Germany
12.5.3.2 France
12.5.3.3 Italy
12.5.3.4 Spain
12.5.3.5 United Kingdom
12.5.4 Japan
13 United States Liver Fibrosis Market
13.1 Liver Fibrosis Market Historical Value (2017-2023)
13.2 Liver Fibrosis Market Forecast Value (2024-2032)
13.2.1 Liver Fibrosis Market by Disease Type
13.2.2 Liver Fibrosis Market by Treatment Type
14 EU-4 and United Kingdom Liver Fibrosis Market
14.1 Liver Fibrosis Market Historical Value (2017-2023)
14.2 Liver Fibrosis Market Forecast Value (2024-2032)
14.3 Germany Liver Fibrosis Market Overview
14.3.1 Liver Fibrosis Market by Disease Type
14.3.2 Liver Fibrosis Market by Treatment Type
14.4 France Liver Fibrosis Market Overview
14.4.1 Liver Fibrosis Market by Disease Type
14.4.2 Liver Fibrosis Market by Treatment Type
14.5 Italy Liver Fibrosis Market Overview
14.5.1 Liver Fibrosis Market by Disease Type
14.5.2 Liver Fibrosis Market by Treatment Type
14.6 Spain Liver Fibrosis Market Overview
14.6.1 Liver Fibrosis Market by Disease Type
14.6.2 Liver Fibrosis Market by Treatment Type
14.7 United Kingdom Liver Fibrosis Market Overview
14.7.1 Liver Fibrosis Market by Disease Type
14.7.2 Liver Fibrosis Market by Treatment Type
15 Japan Liver Fibrosis Market
15.1 Liver Fibrosis Market Historical Value (2017-2023)
15.2 Liver Fibrosis Market Forecast Value (2024-2032)
15.2.1 Liver Fibrosis Market by Disease Type
15.2.2 Liver Fibrosis Market by Treatment Type
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mylan N.V.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Sanofi
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 GlaxoSmithKline plc
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 AstraZeneca
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Johnson & Johnson
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Bristol-Myers Squibb
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Vertex Pharmaceuticals
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 FibroGen, Inc.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Pharmaxis
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Dicerna Pharmaceuticals, Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Dynavax Technologies
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 GlaxoSmithKline plc
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Liver Fibrosis Market - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings